01—Abstract
Summary
Summary of the 8-K filed February 12, 2024. Cited figures are marked; the original filing is the authoritative source.
On February 12, 2024, AbbVie announced in a Form 8-K (Item 7.01 and Exhibit 99.1) that it had completed its acquisition of ImmunoGen, Inc., adding the flagship antibody-drug conjugate ELAHERE (mirvetuximab soravtansine-gynx) to its portfolio.
ELAHERE is approved under accelerated approval for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer, and a confirmatory trial under FDA review reportedly shows a survival benefit. ImmunoGen's Phase 1 FRα ADC IMGN-151 and Phase 2 pivekimab sunirine (anti-CD123, BPDCN, with FDA breakthrough therapy designation) extend the oncology pipeline. Investors should note the price paid: each ImmunoGen share was acquired for $31.26a in cash.
Financially, AbbVie reaffirmed its 2024 full-year adjusted diluted EPS guidance of $11.05b-$11.25, which now includes a $0.42 per share dilutive impact from the ImmunoGen deal and the pending Cerevel Therapeutics acquisition (expected to close mid-2024). The first-quarter 2024 adjusted diluted EPS guidance was lowered from $2.30-$2.34 to $2.26-$2.30 to reflect a $0.04 per share dilution from ImmunoGen. Management expects the deal to be accretive to diluted EPS beginning in 2027 and significantly accretive over the long term.
Guidance excludes acquired IPR&D and milestones, which management says cannot be reliably forecast. The filing is a Regulation FD disclosure, so the press release is not deemed filed under the Exchange Act.
Key risks cited include failure to realize anticipated benefits, integration challenges, transaction costs, unknown liabilities, litigation, and intellectual property challenges. ELAHERE carries a boxed warning for severe ocular toxicities and serious adverse reactions in 31%c of patients, including fatal events in 2%.
02—Key points
Key Highlights
- Completed acquisition of ImmunoGen at $31.26 per share in cash; IMGN stock ceased trading on NASDAQ before market open on February 12, 2024
- ELAHERE (mirvetuximab soravtansine-gynx) is the first and only FDA-approved ADC for ovarian cancer, granted accelerated approval for FRα-positive platinum-resistant ovarian cancer
- Reaffirmed 2024 adjusted diluted EPS guidance of $11.05-$11.25, now including a $0.42 per share dilutive impact from ImmunoGen and the pending Cerevel acquisition
- Lowered Q1 2024 adjusted diluted EPS guidance to $2.26-$2.30 from $2.30-$2.34, reflecting a $0.04 per share dilution from ImmunoGen
- Management expects ImmunoGen to be accretive to diluted EPS beginning in 2027 and significantly accretive over the long term
- Pipeline additions include IMGN-151 (Phase 1 next-generation FRα ADC) and pivekimab sunirine (Phase 2 anti-CD123 ADC for BPDCN, with FDA breakthrough therapy designation)
- ELAHERE carries a boxed warning for severe ocular toxicities; serious adverse reactions occurred in 31% of patients and fatal reactions in 2%
03—Questions
Frequently Asked Questions
What did AbbVie acquire and at what price?
AbbVie acquired all outstanding common stock of ImmunoGen, Inc. for $31.26 per share. The acquisition closed on February 12, 2024, and ImmunoGen is now part of AbbVie.
How does the acquisition affect AbbVie's 2024 earnings guidance?
AbbVie reaffirmed its 2024 full-year adjusted diluted EPS guidance of $11.05-$11.25. That range now includes a $0.42 per share dilutive impact from the ImmunoGen acquisition and the pending Cerevel Therapeutics acquisition. First-quarter 2024 guidance was lowered to $2.26-$2.30 from $2.30-$2.34, including a $0.04 per share dilution from ImmunoGen.
When is the ImmunoGen deal expected to be accretive to earnings?
AbbVie expects the acquisition to be accretive to diluted EPS beginning in 2027 and significantly accretive over the long term. Guidance excludes acquired IPR&D and milestones, which management says cannot be reliably forecast.
What is the main commercial asset AbbVie gained?
ELAHERE (mirvetuximab soravtansine-gynx) is a folate receptor-alpha-directed ADC approved under accelerated approval for FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Continued approval may depend on confirmatory trial results, which the company says are under FDA review and show a survival benefit.
What are the main risks investors should consider?
Risks cited include failure to realize anticipated benefits on the expected timeframe, integration difficulties, significant transaction costs, assumption of unknown liabilities, litigation or regulatory actions, intellectual property challenges, and competition. ELAHERE's boxed warning for severe ocular toxicities and its safety profile, including fatal adverse reactions in 2% of patients, are also relevant.
04—Continue